Dataset Information

A dataset describing a suite of novel antibody reagents for the RAS signaling network

ABSTRACT: RAS genes are frequently mutated in cancer and have for decades eluded effective therapeutic attack. The National Cancer Institute’s RAS Initiative has a focus on understanding pathways and discovering therapies for RAS-driven cancers. Part of these efforts is the generation of novel reagents to enable the quantification of RAS network proteins. Here we present a dataset describing the development, validation (following consensus principles developed by the broader research community), and distribution of 104 monoclonal antibodies (mAbs) enabling detection of 27 phosphopeptides and 69 unmodified peptides from 20 proteins in the RAS network. The dataset characterizes the utility of the antibodies in a variety of applications, including Western blotting, immunoprecipitation, protein array, immunohistochemistry, and targeted mass spectrometry. All antibodies and characterization data are publicly available through the CPTAC Antibody Portal, Panorama Public Repository, and/or PRIDE databases. These reagents will aid researchers in discerning pathways and measuring expression changes in the RAS signaling network.

ORGANISM(S): Homo Sapiens

SUBMITTER: Regine Schoenherr

PROVIDER: PXD012604 | panorama | Tue Sep 03 00:00:00 BST 2019

REPOSITORIES: PanoramaPublic

ACCESS DATA

Publications

A dataset describing a suite of novel antibody reagents for the RAS signaling network.

Schoenherr Regine M RM Huang Dongqing D Voytovich Uliana J UJ Ivey Richard G RG Kennedy Jacob J JJ Saul Richard G RG Colantonio Simona S Roberts Rhonda R RR Knotts Joseph G JG Kaczmarczyk Jan A JA Perry Candice C Hewitt Stephen M SM Bocik William W Whiteley Gordon R GR Hiltke Tara T Boja Emily S ES Rodriguez Henry H Whiteaker Jeffrey R JR Paulovich Amanda G AG

Scientific data 20190829 1

RAS genes are frequently mutated in cancer and have for decades eluded effective therapeutic attack. The National Cancer Institute's RAS Initiative has a focus on understanding pathways and discovering therapies for RAS-driven cancers. Part of these efforts is the generation of novel reagents to enable the quantification of RAS network proteins. Here we present a dataset describing the development, validation (following consensus principles developed by the broader research community), and distr ...[more]

PMID: 31467290

Similar Datasets

Project description:Background: The microtubule-associated protein Tau has attracted a diverse and ever-increasing research interest, with the protein being mentioned in the title/abstract of nearly 34,000 PubMed-indexed publications to-date. To facilitate studies into Tau biology and its role in neurodegeneration, a multitude of Tau-targeting antibodies have been developed, with hundreds of distinct antibody clones currently available for purchase. Nevertheless, concerns over antibody specificity and limited understanding of the performance of many of these reagents has hindered research into the protein. Methods: We have characterised the performance and specificity of 53 commercially-available Tau antibodies by Western blot, 35 of which were additionally profiled by immunohistochemistry. Antibodies were tested for their reactivity to both murine and human samples, with supporting data generated by mass spectrometry-based detection. Results: We show that presumed Tau knockout human cells continue to express residual protein, providing evidence of Tau isoforms generated by exon skipping. Our data also reveals that the binding of several antibodies presumed to detect Tau independently of any post translational modifications (i.e. “total” Tau antibodies, as well as an antibody targeting Asp421-cleaved Tau), were partially inhibited by phosphorylation. Moreover, we found that several total and phospho-Tau antibodies cross-reacted with MAP2 isoforms, while the “oligomer-specific” T22 antibody detected monomeric Tau on Western blot. With one exception, the phosphorylation-dependent Tau antibodies tested were found to not cross-react with the unphosphorylated protein. Importantly, several total and isoform-specific Tau antibodies failed to detect Tau expressed at low endogenous levels, highlighting the importance of antibody choice for studying physiological Tau expression, especially in non-neuronal cells and peripheral tissues. Conclusions: We identify Tau antibodies across all categories (total, PTM-dependent and isoform-specific) that can be employed in Western blotting and/or immunohistochemistry applications to reliably detect even low levels of Tau expression with high specificity. This work represents an extensive resource that serves as a point of reference for future studies with respect to anti-Tau antibody use and development.

Dataset Information

A dataset describing a suite of novel antibody reagents for the RAS signaling network

Publications

A dataset describing a suite of novel antibody reagents for the RAS signaling network.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets